Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ошибки в диагностике и антибактериальнойтерапии внебольничных пневмоний
Ошибки в диагностике и антибактериальнойтерапии внебольничных пневмоний
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ноников В.Е., Воробьева М.Г. Атипичные пневмонии (микоплазмоз, хламидиоз, легионеллез): диагностика и лечение. Справ. поликлин. врача. 2006; 10: 6–9.
2. Ноников В.Е. Дифференциальная диагностика пневмоний и выбор антибактериальной терапии. Клин. фармакол. и тер. 2009; 5: 10–3.
3. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007.
4. Bartlett JG. 2005–6 Pocket Book of Infectious Disease Therapy. Lippincott Williams & Wilkins, 2004.
5. Гилберт Д.Н., Моллеринг Р.С., Эллиопулос Д.М., Сэнд М.А. Сэнфордский спавочник: антимикробная терапия. М.: Эксмо, 2009.
6. Zackon H. Pulmonary Differential Diagnosis. W.B.Saunders. 2000.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
8. Pechere JC, Hughes D, Kardas P et al. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007; 29: 245–53.
9. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. Jama 2001; 286: 49–56.
10. File TM, Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 (Suppl. 3): S159–64.
11. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 2003; 290: 2588–98.
12. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26: 485–90.
13. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001; 33 (Suppl. 3): S187–92.
14. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355.
15. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents 2005; 26 (Suppl. 3): S148–55.
16. File TMJr, Mandell LA, Tillotson G et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60: 112–20.
2. Ноников В.Е. Дифференциальная диагностика пневмоний и выбор антибактериальной терапии. Клин. фармакол. и тер. 2009; 5: 10–3.
3. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007.
4. Bartlett JG. 2005–6 Pocket Book of Infectious Disease Therapy. Lippincott Williams & Wilkins, 2004.
5. Гилберт Д.Н., Моллеринг Р.С., Эллиопулос Д.М., Сэнд М.А. Сэнфордский спавочник: антимикробная терапия. М.: Эксмо, 2009.
6. Zackon H. Pulmonary Differential Diagnosis. W.B.Saunders. 2000.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
8. Pechere JC, Hughes D, Kardas P et al. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007; 29: 245–53.
9. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. Jama 2001; 286: 49–56.
10. File TM, Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 (Suppl. 3): S159–64.
11. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 2003; 290: 2588–98.
12. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26: 485–90.
13. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001; 33 (Suppl. 3): S187–92.
14. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355.
15. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents 2005; 26 (Suppl. 3): S148–55.
16. File TMJr, Mandell LA, Tillotson G et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60: 112–20.
Авторы
В.Е.Ноников
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.